What is the additional mean IOP reduction of fixed combination agents without beta blockers?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

What is the additional mean IOP reduction of fixed combination agents without beta blockers?

Explanation:
In treating POAG, two-drug fixed combinations that do not contain a beta blocker typically provide about 5 mmHg of extra IOP lowering beyond what a single agent achieves. This reflects the additive effect of combining drugs with different mechanisms—such as a prostaglandin analog that increases outflow with an agent that reduces production or increases another outflow pathway—without the systemic concerns of beta blockers. Clinically, trials of non–beta-blocker fixed combinations show a mean additional reduction in the 4–6 mmHg range, with 5 mmHg as a representative average. So, the best answer aligns with this typical additive effect.

In treating POAG, two-drug fixed combinations that do not contain a beta blocker typically provide about 5 mmHg of extra IOP lowering beyond what a single agent achieves. This reflects the additive effect of combining drugs with different mechanisms—such as a prostaglandin analog that increases outflow with an agent that reduces production or increases another outflow pathway—without the systemic concerns of beta blockers. Clinically, trials of non–beta-blocker fixed combinations show a mean additional reduction in the 4–6 mmHg range, with 5 mmHg as a representative average. So, the best answer aligns with this typical additive effect.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy